Form 8-K

8-K — MOLINA HEALTHCARE, INC.

Accession: 0001179929-26-000042

Filed: 2026-10-21

Period: 2026-10-21

CIK: 0001179929

SIC: 6324 (HOSPITAL & MEDICAL SERVICE PLANS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — moh-20261021.htm (Primary)

EX-99.1 (moh3q26_er.htm)

GRAPHIC (molinaa03a01a01a17.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: moh-20261021.htm · Sequence: 1

moh-20261021

0001179929false00011799292026-10-212026-10-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________

FORM 8-K

______________

Current Report

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 21, 2026

______________

MOLINA HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

Delaware 1-31719 13-4204626

(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

______________

200 Oceangate, Suite 100, Long Beach, California 90802

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (562) 435-3666

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Stock, $0.001 Par Value MOH New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.

☐

Item 2.02. Results of Operations and Financial Condition.

On October 21, 2026, Molina Healthcare, Inc. (the “Company”) issued a press release reporting its financial results for the third quarter ended September 30, 2026 and reaffirming the Company’s full-year 2026 earnings guidance. The full text of the press release is included as Exhibit 99.1 to this report. The information contained in the Company’s website cited in the press release is not part of this report.

Note: The information in this Form 8-K and the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No. Description

99.1

Press release of Molina Healthcare, Inc., issued October 21, 2026.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MOLINA HEALTHCARE, INC.

Date:

October 21, 2026

By:

/s/ Jeff D. Barlow

Jeff D. Barlow

Chief Legal Officer and Secretary

EX-99.1

Filename: moh3q26_er.htm · Sequence: 2

Document

News Release

Investor Contact: Jeffrey Geyer, Jeffrey.Geyer@molinahealthcare.com, 305-317-3012

Media Contact: Caroline Zubieta, Caroline.Zubieta@molinahealthcare.com, 562-542-1845

Molina Healthcare Reports Third Quarter 2026 Financial Results

Reaffirms Full Year 2026 Earnings Guidance

Long Beach, Calif., October 21, 2026 – Molina Healthcare, Inc. (NYSE: MOH) (the “Company”) today reported third quarter 2026 GAAP income per diluted share of $0.73 and adjusted income per diluted share of $0.89. Financial results are summarized below:

Three months ended Nine months ended

September 30,

2026 2025 2026 2025

(In millions, except per-share results)

Premium Revenue $10,457 $10,841 $30,873 $32,337

Total Revenue $11,082 $11,477 $32,752 $34,051

GAAP:

Net Income $38 $79 $112 $632

EPS – Diluted $0.73 $1.51 $2.19 $11.79

Medical Care Ratio (MCR) 92.9 % 92.6 % 92.1 % 90.8 %

G&A Ratio 6.4 % 6.4 % 6.8 % 6.5 %

Pre-tax Margin 0.5 % 0.8 % 0.5 % 2.4 %

Adjusted:

Net Income $46 $97 $243 $724

EPS – Diluted $0.89 $1.84 $4.74 $13.49

G&A Ratio 6.3 % 6.3 % 6.6 % 6.4 %

Pre-tax Margin 0.6 % 1.0 % 1.1 % 2.7 %

See the Reconciliation of Unaudited Non-GAAP Financial Measures at the end of this release.

Quarter Highlights

•As of September 30, 2026, the Company served approximately 4.9 million members.

•Premium revenue was approximately $10.5 billion for the third quarter of 2026.

•Third quarter 2026 GAAP income per diluted share was $0.73 and adjusted income per diluted share was $0.89.

•The Company reaffirmed its full year 2026 guidance of expected premium revenue of approximately $42 billion and adjusted earnings of at least $5.25 per diluted share.

“We are pleased with our third quarter results in this challenging environment and reaffirm our full year guidance,” said Joseph Zubretsky, President and Chief Executive Officer. “With the apparent plateauing of medical cost trend, which remains at elevated levels, and the strength of recent rate updates for 2027, we believe we are likely observing the beginning of the turn in Medicaid margins.”

-MORE-

Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results

Page 2

October 21, 2026

Premium Revenue

Premium revenue was approximately $10.5 billion for the third quarter of 2026, a decrease of 4% year over year. The lower premium revenue reflects the impact of lower membership in Medicaid and Marketplace, partially offset by rate updates.

Net Income

GAAP net income for the third quarter of 2026 was $38 million, or $0.73 per diluted share, a decrease of 52% year over year. Adjusted net income for the third quarter of 2026 was $46 million, or $0.89 per diluted share, a decrease of 53% year over year. The decrease is attributed mainly to a higher consolidated MCR.

Medical Care Ratio (MCR)

•The consolidated MCR for the third quarter of 2026 was 92.9%.

•The Medicaid MCR for the third quarter of 2026 was 93.0% and in line with the Company’s expectations, reflecting rate updates and stable medical cost trend.

•The Medicare MCR for the third quarter of 2026 was 93.0% and in line with the Company’s expectations, reflecting stable medical cost trend.

•The Marketplace MCR for the third quarter of 2026 was 92.5% and in line with normal seasonality and the Company’s expectations.

General and Administrative Expense Ratio

The G&A ratio and the adjusted G&A ratio for the third quarter of 2026 were 6.4% and 6.3%, respectively, reflecting continued operating discipline.

Balance Sheet

Cash and investments at the parent company were approximately $608 million as of September 30, 2026, compared to $223 million as of December 31, 2025.

Days in claims payable at September 30, 2026, was 44, consistent with June 30, 2026.

Cash Flow

Operating cash flow for the nine months ended September 30, 2026, was $629 million, compared to an outflow of $237 million for the nine months ended September 30, 2025. The increase compared to the prior year was driven mainly by lower government receivable and payable settlements in 2026.

2026 Guidance

Premium revenue guidance for the full year is unchanged at approximately $42 billion.

The Company expects its full year 2026 GAAP earnings to be at least $2.38 per diluted share and reaffirmed its full year 2026 adjusted earnings of at least $5.25 per diluted share. Guidance metrics across all segments are also reaffirmed. Full year earnings guidance includes a loss of $1.50 per share due to the implementation of the new Florida Medicaid contract in the fourth quarter of 2026 and a loss of $1.00 per share due to performance of the traditional MAPD product, which the Company previously announced it will exit for 2027.

-MORE-

Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results

Page 3

October 21, 2026

Conference Call

Management will host a conference call and webcast to discuss Molina Healthcare’s third quarter ended September 30, 2026 results, at 8:00 a.m. Eastern Time on Thursday, October 22, 2026. The number to call for the interactive teleconference is (877) 883-0383 and the confirmation number is 6534841. A telephonic replay of the conference call will be available through Thursday, October 29, 2026, by dialing (855) 669-9658 and entering confirmation number 4361465. A live audio broadcast of this conference call will be available on Molina Healthcare’s investor relations website, investors.molinahealthcare.com. A 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.

About Molina Healthcare

Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit molinahealthcare.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This earnings release and the Company’s accompanying oral remarks contain forward-looking statements. The Company intends such forward-looking statements to be covered under the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements provide current expectations of future events based on certain assumptions, and all statements other than statements of historical fact contained in this earnings release and the Company’s accompanying oral remarks may be forward-looking statements. In some cases, you can identify forward-looking statements by words such as “guidance,” “future,” “anticipates,” “assumes,” “believes,” “embedded,” “estimates,” “expects,” “growth,” “intends,” “plans,” “predicts,” “projects,” “will,” “would,” “could,” “can,” “may,” or the negative of these terms or other similar expressions. Forward-looking statements contained in this earnings release include, but are not limited to, statements regarding the Company’s 2026 guidance and long-term performance outlook, trends with respect to rates, pretax margins, utilization, and medical costs, including the timing thereof and the anticipated impact on the Company’s business, and our management’s plans and objectives for future operations and business strategy.

Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings “Forward-Looking Statements,” and “Risk Factors,” in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2025, which is on file with the U.S. Securities and Exchange Commission (the “SEC”), and in the Company’s other filings with the SEC, including its Quarterly Reports on Form 10-Q for the period ended March 31, 2026 and June 30, 2026 filed with the SEC and Quarterly Report on Form 10-Q for the period ended September 30, 2026, to be filed with the SEC.

These reports can be accessed under the investor relations tab of the Company’s website or on the SEC’s website at sec.gov. Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that any other results or developments projected or contemplated by its forward-looking statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements. All forward-looking statements in this release represent the Company’s judgment as of October 21, 2026, and, except as otherwise required by law, the Company disclaims any obligation to update any forward-looking statement to conform the statement to actual results or changes in its expectations.

-MORE-

Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results

Page 4

October 21, 2026

MOLINA HEALTHCARE, INC.

UNAUDITED CONSOLIDATED STATEMENTS OF INCOME

Three Months Ended

Nine Months Ended

September 30, September 30,

2026 2025 2026 2025

(In millions, except per-share amounts)

Revenue:

Premium revenue $ 10,457 $ 10,841 $ 30,873 $ 32,337

Premium tax revenue 500 506 1,509 1,325

Investment income 102 108 301 322

Other revenue 23 22 69 67

Total revenue 11,082 11,477 32,752 34,051

Operating expenses:

Medical care costs 9,719 10,044 28,429 29,352

General and administrative expenses 710 729 2,213 2,214

Premium tax expenses 500 506 1,509 1,325

Depreciation and amortization 38 45 117 151

Impairment — — 93 —

Other 9 16 57 66

Total operating expenses 10,976 11,340 32,418 33,108

Operating income 106 137 334 943

Interest expense 53 49 161 140

Income before income tax expense 53 88 173 803

Income tax expense 15 9 61 171

Net income $ 38 $ 79 $ 112 $ 632

Net income per share – Diluted $ 0.73 $ 1.51 $ 2.19 $ 11.79

Diluted weighted average shares outstanding

51.5 52.5 51.3 53.6

-MORE-

Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results

Page 5

October 21, 2026

MOLINA HEALTHCARE, INC.

CONSOLIDATED BALANCE SHEETS

September 30, December 31,

2026 2025

Unaudited

(Dollars in millions,

except per-share amounts)

ASSETS

Current assets:

Cash and cash equivalents $ 4,479 $ 4,248

Investments 4,100 4,008

Receivables 3,359 3,533

Prepaid expenses and other current assets 576 655

Total current assets 12,514 12,444

Property, equipment, and capitalized software, net 324 301

Goodwill and intangible assets, net 2,073 2,195

Restricted investments 345 299

Deferred income taxes, net 267 178

Other assets 129 147

Total assets $ 15,652 $ 15,564

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Medical claims and benefits payable $ 4,988 $ 4,887

Amounts due government agencies 1,141 1,326

Accounts payable, accrued liabilities and other 1,183 1,093

Deferred revenue 82 66

Total current liabilities 7,394 7,372

Long-term debt 3,771 3,766

Finance lease liabilities 179 184

Other long-term liabilities 153 173

Total liabilities 11,497 11,495

Stockholders’ equity:

Common stock, $0.001 par value, 150 million shares authorized; outstanding: 52 million shares at September 30, 2026, and 51 million at December 31, 2025

— —

Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding

— —

Additional paid-in capital 536 452

Accumulated other comprehensive (loss) income (95) 15

Retained earnings 3,714 3,602

Total stockholders’ equity 4,155 4,069

Total liabilities and stockholders’ equity $ 15,652 $ 15,564

-MORE-

Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results

Page 6

October 21, 2026

MOLINA HEALTHCARE, INC.

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

Nine Months Ended

September 30,

2026 2025

(In millions)

Operating activities:

Net income $ 112 $ 632

Adjustments to reconcile net income to net cash provided by (used in) operating activities:

Depreciation and amortization 117 151

Deferred income taxes (54) 37

Share-based compensation

85 27

Impairment 93 —

Other, net

(21) (2)

Changes in operating assets and liabilities:

Receivables 174 (118)

Prepaid expenses and other current assets 11 (25)

Medical claims and benefits payable 101 (157)

Amounts due government agencies (185) (467)

Accounts payable, accrued liabilities and other 88 (195)

Deferred revenue 16 (44)

Income taxes 92 (76)

Net cash provided by (used in) operating activities 629 (237)

Investing activities:

Purchases of investments (1,245) (607)

Proceeds from sales and maturities of investments

1,020 1,017

Purchases of property, equipment, and capitalized software

(94) (102)

Net cash paid in business combinations — (245)

Other, net (9) 19

Net cash (used in) provided by investing activities (328) 82

Financing activities:

Proceeds from borrowings under credit facility and term loans — 1,100

Common stock purchases

— (1,000)

Repayment of credit facility and term loans — (360)

Common stock withheld to settle employee tax obligations (15) (37)

Other, net (16) 35

Net cash used in financing activities (31) (262)

Net increase (decrease) in cash, cash equivalents, and restricted cash and cash equivalents 270 (417)

Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period

4,348 4,741

Cash, cash equivalents, and restricted cash and cash equivalents at end of period

$ 4,618 $ 4,324

-MORE-

Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results

Page 7

October 21, 2026

MOLINA HEALTHCARE, INC.

UNAUDITED SEGMENT DATA

(Dollars in millions)

September 30, December 31, September 30,

2026

2025

Ending Membership by Segment:

Medicaid 4,372,000 4,568,000 4,639,000

Medicare 222,000 262,000 266,000

Marketplace 267,000 655,000 713,000

Other 1,000 6,000 10,000

Total 4,862,000 5,491,000 5,628,000

Three Months Ended September 30,

2026 2025

Premium Revenue Medical

Margin

MCR (1)

Premium Revenue Medical

Margin

MCR (1)

Medicaid $ 8,199 $ 577 93.0 % $ 8,015 $ 639 92.0 %

Medicare 1,616 113 93.0 1,610 103 93.6

Marketplace 642 48 92.5 1,197 53 95.6

Other (2)

— — NM 19 2 NM

Consolidated $ 10,457 $ 738 92.9 % $ 10,841 $ 797 92.6 %

Nine Months Ended September 30,

2026 2025

Premium Revenue Medical

Margin

MCR (1)

Premium Revenue Medical

Margin

MCR (1)

Medicaid $ 24,175 $ 1,793 92.6 % $ 24,174 $ 2,127 91.2 %

Medicare 4,698 413 91.2 4,686 436 90.7

Marketplace 1,994 233 88.3 3,401 411 87.9

Other (2)

6 5 NM 76 11 NM

Consolidated $ 30,873 $ 2,444 92.1 % $ 32,337 $ 2,985 90.8 %

(1)The MCR represents medical costs as a percentage of premium revenue.

(2) The Other MCRs are not meaningful.

-MORE-

Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results

Page 8

October 21, 2026

MOLINA HEALTHCARE, INC.

CHANGE IN MEDICAL CLAIMS AND BENEFITS PAYABLE

(Dollars in millions)

The Company’s claims liabilities include additional reserves to account for moderately adverse conditions based on historical experience and other factors including, but not limited to, variations in claims payment patterns, changes in utilization and cost trends, known outbreaks of disease, and large claims. The Company’s reserving methodology is consistently applied across all periods presented. The amounts displayed for “Components of medical care costs related to: Prior year” represent the amounts by which the original estimates of claims and benefits payable at the beginning of the year were more than the actual liabilities based on information (principally the payment of claims) developed since those liabilities were first reported. The following table presents the components of the change in medical claims and benefits payable for the periods indicated:

Nine Months Ended

September 30,

2026 2025

Unaudited

Medical claims and benefits payable, beginning balance

$ 4,887 $ 4,640

Components of medical care costs related to:

Current year 28,781 29,476

Prior year (352) (124)

Total medical care costs 28,429 29,352

Payments for medical care costs related to:

Current year 24,692 25,425

Prior year 3,963 4,059

Total paid 28,655 29,484

Acquired balances, net of post-acquisition adjustments — 361

Change in non-risk and other payables 327 (25)

Medical claims and benefits payable, ending balance

$ 4,988 $ 4,844

Days in Claims Payable (1)

44 46

__________________

(1)The Company calculates Days in Claims Payable using claims incurred but not paid, or IBNP, and other fee-for-service payables included in medical claims and benefits payable, and quarterly fee-for-service related costs included in medical care costs within the Company’s consolidated financial statements.

-MORE-

Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results

Page 9

October 21, 2026

MOLINA HEALTHCARE, INC.

RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES

(In millions, except per diluted share amounts)

The Company believes that certain non-GAAP (generally accepted accounting principles) financial measures are useful supplemental measures to investors in comparing the Company’s performance to the performance of other public companies in the health care industry. The non-GAAP financial measures are also used internally to enable management to assess the Company’s performance consistently over time. These non-GAAP financial measures, presented below, should be considered as supplements to, and not as substitutes for or superior to, GAAP measures.

Adjustments represent additions and deductions to GAAP net income as indicated in the table below, which include the non-cash impact of amortization of acquired intangible assets, acquisition-related expenses, impairments, and the impact of certain expenses and other items that management believes are not indicative of longer-term business trends and operations.

Adjusted G&A Ratio represents the GAAP G&A ratio, recognizing adjustments.

Adjusted net income represents GAAP net income recognizing the adjustments, net of tax. The Company believes that adjusted net income is helpful to investors in assessing the Company’s financial performance.

Adjusted net income per diluted share represents adjusted net income divided by weighted average common shares outstanding on a fully diluted basis.

Adjusted pre-tax margin represents adjusted income before income tax expense, divided by total revenue.

Three Months Ended September 30, Nine Months Ended September 30,

2026 2025 2026 2025

Amount Per Diluted Share Amount Per Diluted Share Amount Per Diluted Share Amount Per Diluted Share

GAAP Net income

$ 38 $ 0.73 $ 79 $ 1.51 $ 112 $ 2.19 $ 632 $ 11.79

Adjustments:

Amortization of intangible assets

$ 10 $ 0.19 $ 20 $ 0.37 $ 29 $ 0.56 $ 73 $ 1.35

Acquisition-related expenses (1)

— — 4 0.07 33 0.61 46 0.86

Impairment (2)

— — — — 93 1.82 — —

Other (3)

— — (1) (0.01) 21 0.44 1 0.02

Subtotal, adjustments

10 0.19 23 0.43 176 3.43 120 2.23

Income tax effect

(2) (0.03) (5) (0.10) (45) (0.88) (28) (0.53)

Adjustments, net of tax

8 0.16 18 0.33 131 2.55 92 1.70

Adjusted net income

$ 46 $ 0.89 $ 97 $ 1.84 $ 243 $ 4.74 $ 724 $ 13.49

__________________

(1)Reflects non-recurring costs associated with acquisitions, including various transaction and certain integration costs.

(2)This impairment charge results from the Company’s decision to exit the Medicare Advantage Prescription Drug product for 2027 as that product does not align with the Company’s strategic shift to focus exclusively on dual eligible members in Medicare.

(3)The nine months ended September 30, 2026 primarily includes non-recurring termination benefits, and the nine months ended September 30, 2025 includes non-recurring litigation costs.

-MORE-

Molina Healthcare, Inc. Reports Third Quarter 2026 Financial Results

Page 10

October 21, 2026

MOLINA HEALTHCARE, INC.

RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES (CONTINUED)

2026 GUIDANCE

Amount

Per Diluted Share (2)

GAAP Net income

$ 122 $ 2.38

Adjustments:

Acquisition-related expenses

48 0.89

Amortization of intangible assets 36 0.70

Impairment 93 1.82

Other 21 0.44

Subtotal, adjustments

198 3.85

Income tax effect (1)

(50) (0.98)

Adjustments, net of tax

148 2.87

Adjusted net income

$ 270 $ 5.25

__________________

(1)Income tax effect calculated at the statutory tax rate of approximately 25.5%.

(2)Computations assume approximately 51.4 million diluted weighted average shares outstanding.

-END-

GRAPHIC

Filename: molinaa03a01a01a17.jpg · Sequence: 6

Binary file (79878 bytes)

Download molinaa03a01a01a17.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover Page Document

Oct. 21, 2026

Cover [Abstract]

Entity Central Index Key

0001179929

Document Type

8-K

Entity Emerging Growth Company

false

Title of 12(b) Security

Common Stock, $0.001 Par Value

Entity Incorporation, State or Country Code

Entity File Number

1-31719

Entity Tax Identification Number

13-4204626

Trading Symbol

MOH

Security Exchange Name

NYSE

Document Period End Date

Oct. 21, 2026

Entity Registrant Name

MOLINA HEALTHCARE, INC.

City Area Code

562

Local Phone Number

435-3666

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Amendment Flag

false

Entity Address, Address Line One

200 Oceangate, Suite 100,

Entity Address, City or Town

Long Beach,

Entity Address, State or Province

Entity Address, Postal Zip Code

90802

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration